More recently, Martignoni et al (2005) have suggested that interleukin (IL)-6 overexpression in pancreatic cancer patients is related to the ability of certain IL-6 producing tumours to sensitise PBMC and induce IL-6 expression in PBMCs. Here, IL6 is linked to familial pancreatic carcinoma.